Discounted Cash Flow
Bicycle Therapeutics Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | $2.1m | $-16.3m | $-2.5m | -790.4% | $-48.81 |
| 2018 | $7.1m (246.4%) | $-22.2m (-36.6%) | $-27.3m (-978.5%) | -311.7% (60.6%) | $-49.78 (-2.0%) |
| 2019 | $13.8m (93.4%) | $-30.9m (-38.8%) | $-664.0k (97.6%) | -223.6% (28.3%) | $-2.77 (94.4%) |
| 2020 | $10.4m (-24.7%) | $-51.7m (-67.6%) | $-239.0k (64.0%) | -497.9% (-122.7%) | $-2.66 (4.0%) |
| 2021 | $11.7m (12.6%) | $-68.5m (-32.4%) | $13.5m (5757.7%) | -585.5% (-17.6%) | $-2.67 (-0.4%) |
| 2022 | $14.5m (23.6%) | $-114.2m (-66.8%) | $1.6m (-88.5%) | -789.9% (-34.9%) | $-3.80 (-42.3%) |
| 2023 | $27.0m (86.5%) | $-179.2m (-56.9%) | $2.2m (38.4%) | -664.3% (15.9%) | $-5.08 (-33.7%) |
| 2024 | $35.3m (30.8%) | $-173.8m (3.0%) | $5.8m (168.4%) | -492.7% (25.8%) | $-2.90 (42.9%) |
| 2025 | $72.6m (105.8%) | $-218.8m (-25.9%) | $10.0m (73.6%) | -301.4% (38.8%) | $-3.16 (-9.0%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.